Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explainer

Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.

Explainer

GLP-1 drugs and ankle OA: new cohort data

A Johns Hopkins cohort study found obese GLP-1 users had lower rates of ankle injection and arthroplasty. Diabetic users showed higher arthroscopy rates.

19 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Hunger pain: semaglutide in schizophrenia

A qualitative study asked people with schizophrenia how semaglutide changed the hunger antipsychotics can cause.

19 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide lowers hsCRP in SELECT

A Circulation analysis of SELECT finds semaglutide 2.4 mg reduces hsCRP in adults with prior heart attack or stroke. What it means, and what it doesn't.

19 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Sleep and mood after starting GLP-1 drugs

A new observational study links tirzepatide and semaglutide to improved sleep and depression scores at three months, with caveats.

19 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Doctor suspended over Ozempic to partner

A GMC tribunal suspended a UK doctor for prescribing Ozempic and Wegovy, both semaglutide, to her partner without disclosure.

18 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Experts Issue GLP-1 Guidance for NET Care

A new expert consensus statement sets ground rules for using GLP-1 drugs like tirzepatide in neuroendocrine tumor patients.

18 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Can incretins ease psoriasis inflammation?

A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.

18 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide Plus Luseogliflozin for MASH

A small randomised trial tested adding the SGLT2 drug luseogliflozin to semaglutide for MASH. Here is what the numbers did and did not show.

18 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Ozempic in Pro-Eating-Disorder Communities

A 2026 study finds Ozempic, a semaglutide brand, is normalized more than warned against in a pro-eating-disorder community on X.

18 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide and aspiration risk in surgery

New ultrasound data and case reports on semaglutide, retained gastric content and aspiration are reshaping the pre-surgery cessation question.

18 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tesamorelin and ipamorelin: side effects

Racing heart, flushing, and dizziness after combining tesamorelin and ipamorelin with TRT: what the evidence says and when to seek care.

18 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Thymosin β4 curbs colitis in mouse study

A 2026 mouse study found thymosin beta-4, the peptide sold as TB-500, eased colitis and gut fibrosis through a newly proposed receptor pathway.

18 Aug 2026 · PeptideMethods Editorial Team · 4 min read